ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic… Read more
ENDRA Life Sciences Inc (NDRA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -6.792x
Based on the latest financial reports, ENDRA Life Sciences Inc (NDRA) has a cash flow conversion efficiency ratio of -6.792x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.16 Million) by net assets ($171.38K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ENDRA Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how ENDRA Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ENDRA Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ENDRA Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tarapur Transformers Limited
NSE:TARAPUR
|
1.083x |
|
Aeva Technologies, Inc. Warrants
NYSE:AEVAW
|
-0.973x |
|
Bioxytran Inc
OTCQB:BIXT
|
0.014x |
|
Ginting Jaya Energi
JK:WOWS
|
0.023x |
|
Akkhie Prakarn Public Company Limited
BK:AKP
|
0.046x |
|
Golden Land Bhd
KLSE:7382
|
-0.063x |
|
BTM Resources Bhd
KLSE:7188
|
-0.033x |
|
Paras Petrofils Limited
NSE:PARASPETRO
|
N/A |
Annual Cash Flow Conversion Efficiency for ENDRA Life Sciences Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of ENDRA Life Sciences Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.56 Million | $-7.40 Million | -2.890x | -71.30% |
| 2023-12-31 | $5.66 Million | $-9.55 Million | -1.687x | +4.80% |
| 2022-12-31 | $7.20 Million | $-12.77 Million | -1.772x | -71.85% |
| 2021-12-31 | $10.78 Million | $-11.12 Million | -1.031x | +31.35% |
| 2020-12-31 | $7.17 Million | $-10.77 Million | -1.502x | +16.73% |
| 2019-12-31 | $4.76 Million | $-8.59 Million | -1.804x | -46.35% |
| 2018-12-31 | $6.25 Million | $-7.70 Million | -1.233x | -97.02% |
| 2017-12-31 | $5.28 Million | $-3.30 Million | -0.626x | -142.51% |
| 2016-12-31 | $-893.77K | $-1.32 Million | 1.472x | +143.72% |
| 2015-12-31 | $250.30K | $-842.73K | -3.367x | -45.87% |
| 2014-12-31 | $605.33K | $-1.40 Million | -2.308x | -- |